Hydroxygenkwanin suppresses proliferation, invasion and migration of osteosarcoma cells via the miR‑320a/SOX9 axis

Related Experiment Video

Updated: Sep 2, 2025

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma
08:07

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma

Published on: April 12, 2019

7.3K

Xinli Dong1, Yanhua Wang2, Hua Zhuang1

  • 1Department of Orthopedics, Traditional Chinese Medicine Hospital of Binzhou, Binzhou, Shandong 256600, P.R. China.

Molecular Medicine Reports
|August 5, 2022
PubMed

Insights

Hydroxygenkwanin (HGK) inhibits osteosarcoma cell growth and spread by increasing microRNA-320a (miR-320a) and decreasing SOX9. This study reveals HGK

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Hydroxygenkwanin (HGK) exhibits anticancer properties in various tumors.
  • The therapeutic potential of HGK in osteosarcoma remains unexplored.
  • Understanding HGK's molecular mechanisms is crucial for its clinical application.

Purpose of the Study:

  • To investigate the therapeutic effects of HGK on osteosarcoma.
  • To elucidate the specific molecular mechanisms underlying HGK's action in osteosarcoma.
  • To explore the role of the miR-320a/SOX9 axis in HGK-mediated osteosarcoma inhibition.

Main Methods:

  • Osteosarcoma cell lines (MG-63, U2OS) were treated with HGK.
  • Cell viability, proliferation, migration, and invasion were assessed using MTT, clone formation, wound healing, and Transwell assays.
  • Expression levels of miR-320a, SOX9, and EMT-related proteins were analyzed via RT-qPCR and Western blot.

Main Results:

  • HGK inhibited osteosarcoma cell proliferation, migration, and invasion.
  • HGK treatment upregulated miR-320a expression and downregulated SOX9 expression.
  • The miR-320a/SOX9 axis was identified as a key mediator of HGK's anti-osteosarcoma effects.

Conclusions:

  • HGK demonstrates significant therapeutic potential against osteosarcoma.
  • HGK exerts its anti-cancer effects by modulating the miR-320a/SOX9 signaling pathway.
  • Targeting the miR-320a/SOX9 axis could be a promising strategy for osteosarcoma treatment.
Keywords:
hydroxygenkwanininvasionmiR‑320a/SOX9 axismigrationosteosarcomaproliferation

More Related Videos

Intratibial Osteosarcoma Cell Injection to Generate Orthotopic Osteosarcoma and Lung Metastasis Mouse Models04:25

Intratibial Osteosarcoma Cell Injection to Generate Orthotopic Osteosarcoma and Lung Metastasis Mouse Models

Published on: October 28, 2021

9.7K
Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

1.7K

Related Concept Videos

Osteoclasts in Bone Remodeling01:31

Osteoclasts in Bone Remodeling

Osteoclasts are cells responsible for bone resorption and remodeling. They originate from hematopoietic progenitor cells present in the bone marrow. Numerous progenitor cells fuse to form multinucleated cells, each with 10-20 nuclei. A single osteoclast has a diameter of 150 to 200 µM. These cells have ruffled borders that break down the underlying bone tissue and release minerals such as calcium into the blood in bone resorption. Osteoclasts cling to bones with their ruffled edges during...
3.1K
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.7K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.9K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K
Hypoxia01:23

Hypoxia

Hypoxia is a medical condition characterized by an inadequate oxygen supply to body tissues. It typically manifests as a bluish discoloration of the skin and mucosae, especially in fair-skinned individuals, when hemoglobin (Hb) saturation drops below 75%.
Types of Hypoxia
There are four primary types of hypoxia, each resulting from a different cause:
1. Anemic hypoxia: This type occurs due to insufficient oxygen delivery caused by a lack of red blood cells (RBCs) or RBCs with abnormal or...
1.2K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.9K